Study of long-term effects of CFTR modulator medicines in CF
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been prescribed a CFTR modulator medicine and plan to start it within 30 days
- Or you plan to switch from one CFTR modulator to another within 30 days
- You are enrolled in the Canadian Cystic Fibrosis Registry (CCFR)
- You (or your parent/legal guardian) can provide consent, and you can assent if needed
- You do not have known reasons you cannot take CFTR modulator medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study looks at how cystic fibrosis care is organized when patients take highly effective CFTR modulator drugs. It aims to understand if care needs change for those on modulators compared to those who cannot take them.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.